OPGN

OpGen Inc

OPGN, USA

OpGen, Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company's products include Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits. It also provides laboratory services; collaboration services, including funded software arrangements; and license arrangements services. In addition, the company offers listing sponsorship and consultancy services. OpGen, Inc. was incorporated in 2001 and is based in Clarksburg, Maryland.

https://www.opgen.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
OPGN
stock
OPGN

OpGen Appoints New CEO Christian-Laurent Bonte TipRanks

Read more →
OPGN
stock
OPGN

OpGen (OTC:OPGN) Stock Price Crosses Above 50-Day Moving Average – Here’s Why Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$3

Analyst Picks

Strong Buy

0

Buy

0

Hold

1

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very Low

45.28

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

10.09

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-5.99 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-4.82 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-8.33 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.24

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 4.98% of the total shares of OpGen Inc

1.

Chase Investment Counsel Corp

(2.6289%)

since

2024/03/31

2.

Fidelity Extended Market Index

(0.5157%)

since

2024/06/30

3.

Vanguard Group Inc

(0.422%)

since

2024/03/31

4.

Vanguard Institutional Extnd Mkt Idx Tr

(0.395%)

since

2024/06/30

5.

Geode Capital Management, LLC

(0.2875%)

since

2024/03/31

6.

NT Ext Equity Mkt Idx Fd - L

(0.2315%)

since

2024/06/30

7.

Northern Trust Extended Eq Market Idx

(0.2315%)

since

2024/06/30

8.

BlackRock Inc

(0.1263%)

since

2024/03/31

9.

Fidelity Total Market Index

(0.0225%)

since

2024/06/30

10.

Fidelity Series Total Market Index

(0.0203%)

since

2024/06/30

11.

SSgA U.S. Extended Market Index Class I

(0.0144%)

since

2023/12/31

12.

State St US Extended Mkt Indx NL Cl C

(0.0144%)

since

2024/06/30

13.

NT Ext Equity Mkt Idx Fd - NL

(0.0138%)

since

2024/03/31

14.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.011%)

since

2024/06/30

15.

Fidelity Nasdaq Composite Index

(0.0096%)

since

2024/05/31

16.

Qube Research & Technologies

(0.0095%)

since

2024/03/31

17.

BNYM Mellon SL Market Completion UC1

(0.0075%)

since

2024/06/30

18.

Spartan Total Market Index Pool E

(0.0066%)

since

2024/06/30

19.

SSgA U.S. Total Market Index Strategy

(0.0059%)

since

2024/06/30

20.

Spartan Extended Market Index Pool E

(0.0019%)

since

2024/06/30

21.

State St US Ttl Mkt Indx SL Cl I

(0.0019%)

since

2024/06/30

22.

Wells Fargo & Co

(0.0006%)

since

2024/03/31

23.

NT US Market Cap Idx Fd - L

(0.0006%)

since

2023/12/31

24.

Northern Trust Wilshire 5000

(0.0006%)

since

2024/06/30

25.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0005%)

since

2024/03/31

26.

BNYM Mellon NSL Mkt Completion Fund Inst

(0.0005%)

since

2024/06/30

27.

Royal Bank of Canada

(0.0004%)

since

2024/03/31

28.

Goss Wealth Management LLC

(0.0004%)

since

2024/03/31

29.

UBS Group AG

(0.0001%)

since

2024/03/31

30.

Bank of America Corp

(0%)

since

2024/03/31

31.

Renaissance Technologies Corp

(0%)

since

2024/03/31

32.

Virtu Financial LLC

(0%)

since

2024/03/31

33.

Focused Wealth Strategies, INC.

(0%)

since

2024/03/31

34.

TWO SIGMA SECURITIES, LLC

(0%)

since

2024/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.0604

EPS Estimate

—

EPS Difference

0

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1.5)
Momentum
Moderate Momentum(6)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.